Mark's experience is no longer a curiosity. It is a pattern.
Across research hospitals, clinical trials, and patient communities from Boston to Mumbai, a striking realisation is spreading through the medical world: Ozempic and its family of drugs are doing far more than helping people lose weight. They appear to be quietly rewiring the brain's relationship with craving itself. They are protecting the heart in ways that no weight loss drug has ever done before. And they may, if current trials confirm what early evidence is suggesting, become one of the most significant tools ever developed against Alzheimer's disease.
This is the story of a drug that was designed to control blood sugar, accidentally transformed the obesity treatment landscape, and is now threatening to upend medicine in ways nobody planned.
What Exactly Is a GLP-1 Drug?
Before going further, let us establish what we are actually talking about.
GLP-1 stands for Glucagon-Like Peptide-1. It is a hormone that your small intestine naturally produces after you eat a meal. Its job is to signal your pancreas to release insulin, to slow down digestion, and critically, to tell your brain that you are full. It is part of the body's built-in appetite control system.
GLP-1 receptor agonists are drugs that mimic this hormone, but with far greater potency and for a much longer duration than the body's natural version. The most famous of them is semaglutide, sold as Ozempic for diabetes and Wegovy for weight management. Other drugs in this class include liraglutide (sold as Victoza or Saxenda), and tirzepatide (Mounjaro and Zepbound), which targets both GLP-1 and another hormone called GIP.
Here is the key fact that unlocks everything else in this article. GLP-1 receptors are not only in the stomach and pancreas. They are distributed across the heart, the kidneys, the lungs, the arteries and veins, and crucially, throughout the brain, including in regions governing reward, memory, impulse control, and decision making. When a drug activates all of those receptors simultaneously, the effects go well beyond appetite suppression. And that is precisely what researchers are now discovering in study after study.
Part One: The Heart Story. A Drug That Does What No Weight Loss Treatment Has Done Before
Heart disease kills more people globally than any other condition. In the United States alone, it claims roughly one life every 34 seconds. For decades, the relationship between obesity and heart disease was well understood, but treating obesity to protect the heart had never been proven in a rigorous clinical trial.
That changed in 2023.
The SELECT trial, one of the most significant cardiovascular studies in recent history, enrolled over 17,500 adults across 41 countries. These were people who had overweight or obesity and had already experienced a heart attack, stroke, or peripheral artery disease. Critically, none of them had diabetes. They were given either weekly injections of semaglutide or a placebo and followed for over three years.
The result was decisive. People taking semaglutide had a 20% lower risk of heart attack, stroke, or death from cardiovascular disease compared to the placebo group. This was the first time in medical history that any medication or lifestyle therapy had been proven to reduce major cardiovascular events in people with overweight or obesity who did not have diabetes.
In May 2024, the FDA formally approved Wegovy for cardiovascular risk reduction, the first weight loss drug in history to receive that specific designation.
But the SELECT trial did not stop revealing surprises. A further analysis published in The Lancet examined a subgroup of around 4,300 participants who also had heart failure. Semaglutide delivered similar cardiovascular protection in these patients too. Separate trials, the STEP-HFpEF studies, showed that semaglutide improved quality of life and exercise performance in patients with a specific and notoriously difficult type of heart failure called heart failure with preserved ejection fraction, a condition that until recently had almost no effective treatments.
How does it work on the heart? The exact mechanism is still being studied, but researchers believe it involves multiple pathways working simultaneously: improvements in blood pressure, reductions in LDL cholesterol, direct anti-inflammatory effects on the arterial walls, and direct protective effects on the heart muscle itself. This is not just the heart benefiting because people are losing weight. The cardiovascular benefits appear to occur regardless of the starting weight or the amount of weight actually lost during the trial.
That is a major scientific clue. It tells us the drug is doing something directly to the cardiovascular system, beyond simply reducing the physical burden of obesity on the heart.
Part Two: The Brain and Addiction. A Discovery Nobody Saw Coming
This is where the story gets genuinely strange, and genuinely exciting.
Patricia Grigson is a professor and chair of the Department of Neuroscience and Experimental Therapeutics at Penn State College of Medicine. In 2018, she began studying what happened when rodents addicted to heroin were given a GLP-1 agonist. The animals reduced their heroin seeking behaviour significantly. More remarkably, they also showed a reduced chance of relapse, even when exposed to the cues, the drug itself, and the stressors that normally trigger drug seeking. The drug was quieting the addiction circuitry, not just the hunger circuitry.
This makes biological sense once you understand where the GLP-1 receptors sit in the brain. They are heavily expressed in the nucleus accumbens, the brain's primary reward centre, the same region that drives the compulsive seeking of food, drugs, alcohol, gambling, and other addictive behaviours. When semaglutide activates receptors in this region, it appears to dampen the dopamine spike, the surge of pleasure and motivation that makes an addictive substance feel irresistible. It does not eliminate pleasure. It reduces the urgency of craving.
This is exactly the mechanism behind its effect on overeating. But overeating and drug addiction are rooted in the same neural machinery. The drug, it turns out, does not discriminate.
A 2024 study published in Nature Medicine examined electronic health records from over 500,000 patients and found that those taking semaglutide had significantly lower rates of opioid overdose events, alcohol related hospitalisations, and nicotine cessation failures compared to matched controls on other medications. The effect sizes were modest but consistent across demographic groups.
A WashU Medicine study published in early 2025, one of the most comprehensive analyses of GLP-1 drugs to date, found that people taking these medications had reduced risks of addiction to alcohol, cannabis, stimulants, and opioids. The researchers specifically noted that GLP-1 receptors are expressed in brain areas involved in impulse control, reward, and addiction, which may explain the pattern.
By 2025, more than 15 clinical trials were underway globally to formally test GLP-1 drugs against substance use disorders. Brigham and Women's Hospital's Division of Addiction Psychiatry is running two trials simultaneously, one for opioid use disorder and one for alcohol use disorder. The FDA has not approved these drugs for addiction treatment yet, as formal trial data is still accumulating. But what doctors are hearing from patients taking these medications for diabetes or weight loss is impossible to ignore.
"It just silenced that noise," one patient told researchers. "It allows them to make better choices."
Opioid use disorder alone killed approximately 87,000 people in the United States in 2024. If a drug already on the market, already widely prescribed, can meaningfully reduce the grip of addiction, the public health implications are enormous.
Part Three: The Alzheimer's Possibility. Science's Most Cautious Hope
Alzheimer's disease currently has no cure. Existing treatments slow its progression modestly at best, and carry significant costs and risks. About 55 million people worldwide live with dementia, a number projected to triple by 2050. Even a modest, safe intervention that reduces risk or slows progression would be transformative.
The early evidence from GLP-1 research is cautious but striking.
The WashU Medicine study, published in January 2025, found a reduced risk of neurocognitive disorders including Alzheimer's and dementia among GLP-1 drug users. The researchers estimated a roughly 8 to 12 percent reduction in risk, which is modest on the surface but significant in the context of a disease that has resisted almost every therapeutic approach.
A separate large scale retrospective study published in 2025, using health records from 147,505 matched pairs from 142 healthcare organisations, found something more dramatic. GLP-1 receptor agonist users had a dementia incidence of 0.20% versus 0.44% in non-users, translating to roughly a 70% reduced relative risk of developing dementia. The researchers were careful to note the limitations of observational data, and that this level of risk reduction needs to be confirmed in randomised trials. But the signal is consistent and it is appearing repeatedly across different populations and different study designs.
What could explain it? The proposed mechanisms are biologically plausible. GLP-1 drugs reduce inflammation throughout the body, including in the brain.
Neuroinflammation is now understood to be a major driver of Alzheimer's progression. The drugs also improve insulin signalling in the brain. Alzheimer's has been controversially but increasingly described as a form of metabolic dysfunction in brain cells, sometimes called Type 3 diabetes, and improving the brain's ability to use glucose could slow neurodegeneration. Animal studies have also shown that GLP-1 drugs can reduce the buildup of amyloid plaques, the abnormal protein deposits that are a hallmark of Alzheimer's disease.
In 2024, the first meaningful human trial data arrived. The ELAD trial, led by Professor Paul Edison of Imperial College London, enrolled 204 patients with mild Alzheimer's disease across 24 UK clinics. Half received daily liraglutide and half received a placebo for one year. The trial found that liraglutide appeared to reduce shrinkage in the parts of the brain controlling memory, learning, language, and decision making by nearly 50% compared to placebo. The primary endpoint of the study was not met, meaning it was not definitive proof of benefit in cognitive terms. But the brain protection signal was real enough to launch the next phase.
The EVOKE studies are the largest trials ever conducted with a GLP-1 drug in Alzheimer's disease. About 1,800 people with early Alzheimer's enrolled globally in 2021. Results were expected in late 2025. If those results confirm meaningful benefit, FDA approval for this indication could follow in 2027 or 2028, giving millions of families something the medical world has never been able to offer them: a realistic hope of slowing the disease that is robbing someone they love of their identity.
As one NIH researcher from the National Institute on Aging put it, the apparent usefulness of these drugs may lie in the fact that the GLP-1 receptor is distributed across nearly every major organ and tissue in the body, including the brain. Equally important, numerous diseases are likely driven by common fundamental mechanisms including inflammation, insulin resistance, and oxidative stress, all of which GLP-1 drugs can positively impact.
The Scale of the Discovery: 42 Conditions and Counting
In January 2025, a WashU Medicine research team published perhaps the most ambitious analysis of GLP-1 drugs yet conducted. They examined health outcomes across 175 conditions in hundreds of thousands of patients. Compared to usual care, GLP-1 drug use was associated with decreased risk in 42 health outcomes, covering nearly a quarter of all conditions studied.
Beyond the headlines of addiction, dementia, and heart disease, the drugs were also associated with reduced risks of seizures, suicidal ideation, self-harm, schizophrenia and other psychotic disorders, respiratory failure, sepsis, chronic obstructive pulmonary disease, blood clots in the lungs, and even certain liver cancers.
The research also confirmed what the FLOW trial demonstrated separately at the American Heart Association's 2024 Scientific Sessions: semaglutide reduced the progression of chronic kidney disease by approximately 24% in high-risk patients.
The common thread through all of these effects is not weight loss. It is systemic inflammation, metabolic dysfunction, and the distribution of GLP-1 receptors across every major system in the human body. These drugs appear to be addressing a set of root causes that underlie a remarkably wide range of diseases.
The lead researcher described the drug's effect on Alzheimer's as "a side gig. Nobody designed GLP-1s to reduce Alzheimer's disease." That observation captures something profound about how medical discovery sometimes works. The most important breakthroughs are often found in the territory that nobody went looking for.
The Side Effects and the Risks: This Is Not a Magic Drug
None of the above means GLP-1 drugs are without risk. Intellectual honesty demands that the other side of this story be told clearly.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These typically occur when the drug is first started or when the dose is increased, and they generally improve over time. They are unpleasant enough that in the SELECT trial, 16.6% of semaglutide users discontinued versus 8.2% on placebo, almost entirely due to gut related symptoms.
More seriously, the WashU Medicine 2025 study also found increased risks for pancreatitis, kidney complications, and gastrointestinal disorders. These are uncommon, but they can be severe, and kidney problems in particular can progress without obvious symptoms until the condition is advanced.
There are also open questions about thyroid C-cell tumours, a risk observed in rodent models that has not been confirmed in humans but that continues to be monitored. The FDA in early 2024 also began evaluating reports of hair loss and, in some cases, suicidal ideation in GLP-1 users, although a direct causal link has not been established.
The honest summary is this: GLP-1 drugs carry real benefits and real risks. The benefits are, in many cases, substantial. The risks are, for most patients, manageable with appropriate medical supervision. But these are powerful systemic drugs acting on multiple organ systems simultaneously, and they are relatively new. The 10 to 20 year picture is still being written.
There is also the issue of access. Wegovy costs approximately $1,350 for a 28-day supply in the United States. Novo Nordisk launched a reduced cost direct to patient option at $499 per month in 2025, but that remains out of reach for millions. Insurance coverage is inconsistent. And there is a documented four-fold difference in prescription rates between White and Black patients in the United States, reflecting deep structural inequities in who benefits from medical breakthroughs. A drug that could protect against heart disease, addiction, and Alzheimer's simultaneously is only a revolution if people can actually get it.
What This Means for Medicine
Let us step back and appreciate what is happening here.
For most of the history of pharmacology, drugs were designed to hit a single target: one receptor, one pathway, one disease. The GLP-1 receptor agonists are forcing a rethink of that model. Here is a class of drugs that, by activating a single receptor type that happens to be everywhere in the body, appears to be addressing inflammation, metabolic dysfunction, reward circuitry, cardiovascular risk, and neurodegeneration all at once.
That is not how drugs are supposed to work. That is not how we designed them or thought about them. And yet here it is, in the data, again and again across independent research teams and institutions.
Harvard researchers have framed it this way: GLP-1 drugs influence the central cardio-kidney-metabolic process, an overarching biological system rather than a single isolated disease pathway. By targeting the fundamental drivers of this system, excess weight and metabolic dysfunction, the drugs affect a cascade of related conditions simultaneously.
This may represent not just a new drug but a new way of thinking about disease itself. Many conditions we treat separately, heart disease, addiction, dementia, metabolic syndrome, chronic kidney disease, may share deeper biological roots that a single well targeted intervention can address.
Conclusion: A Lunchtime Discovery That Became a Revolution
Ozempic began as a diabetes drug. It became a weight loss phenomenon. Now it is something altogether larger and harder to categorise: a systemic intervention whose full scope medicine is still in the process of discovering.
The numbers are serious. A 20% reduction in heart attacks and strokes. A potential 70% reduction in dementia risk in early observational studies. Consistent reduction in addiction related events across multiple substances. Decreased risk across 42 separate health conditions in one of the most comprehensive analyses ever conducted.
None of this means GLP-1 drugs are a miracle cure. They have real side effects, serious monitoring requirements, deep access inequities, and many questions that long term follow up has not yet answered. They work best as part of a broader approach that includes lifestyle changes and appropriate medical care.
But the trajectory is undeniable. A drug that was designed to lower blood sugar after meals appears to be reshaping how we understand the human body's most fundamental biological systems, and doing so across a range of conditions that have killed and disabled hundreds of millions of people worldwide.
The science is not finished. The EVOKE trial results, the addiction trials, and years of further follow up data will sharpen or revise what we know today. But the direction of travel is clear.
We designed Ozempic to control blood sugar. What we got was something far more interesting: a window into the biology that ties our heart, our brain, our appetite, and our vulnerabilities together, and perhaps, the first drug that can address all of them at once.
Sources: WashU Medicine (January 2025), Nature Medicine, American Heart Association SELECT Trial results, Yale Medicine, Harvard Gazette (February 2026), AAMC, Alzheimer's Association International Conference 2024 (AAIC), BrightFocus Foundation, Cleveland Clinic, UCL, The Lancet, Altitudes Magazine, Vedantu, Indiana University School of Medicine Bioethics.
0 Comments